{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:03:13Z","timestamp":1774627393694,"version":"3.50.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.phrs.2022.106316","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T11:35:47Z","timestamp":1655465747000},"page":"106316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Comparative efficacy and safety of therapeutics for elderly glioblastoma patients: A Bayesian network analysis"],"prefix":"10.1016","volume":"182","author":[{"given":"Binghao","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanzhang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12 Suppl. 2","key":"10.1016\/j.phrs.2022.106316_bib1","doi-asserted-by":"crossref","first-page":"Siv1","DOI":"10.1093\/neuonc\/noaa200","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017","volume":"22","author":"Ostrom","year":"2020","journal-title":"Neuro-Oncology"},{"issue":"12 Suppl. 2","key":"10.1016\/j.phrs.2022.106316_bib2","doi-asserted-by":"crossref","first-page":"Siii1","DOI":"10.1093\/neuonc\/noab200","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018","volume":"23","author":"Ostrom","year":"2021","journal-title":"Neuro-Oncology"},{"issue":"1","key":"10.1016\/j.phrs.2022.106316_bib3","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/curroncol29010032","article-title":"Treatment of older adult patients with glioblastoma: moving towards the inclusion of a comprehensive geriatric assessment for guiding management","volume":"29","author":"Chahal","year":"2022","journal-title":"Curr. Oncol."},{"issue":"7721","key":"10.1016\/j.phrs.2022.106316_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41586-018-0457-8","article-title":"Facing up to the global challenges of ageing","volume":"561","author":"Partridge","year":"2018","journal-title":"Nature"},{"issue":"7764","key":"10.1016\/j.phrs.2022.106316_bib5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41586-019-1365-2","article-title":"From discoveries in ageing research to therapeutics for healthy ageing","volume":"571","author":"Campisi","year":"2019","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.phrs.2022.106316_bib6","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2022.106316_bib7","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ctrv.2012.05.008","article-title":"Optimal management of elderly patients with glioblastoma","volume":"39","author":"Laperriere","year":"2013","journal-title":"Cancer Treat. Rev."},{"issue":"8","key":"10.1016\/j.phrs.2022.106316_bib8","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","article-title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","volume":"22","author":"Wen","year":"2020","journal-title":"Neuro-Oncology"},{"issue":"3","key":"10.1016\/j.phrs.2022.106316_bib9","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2022.106316_bib10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1200\/JCO.21.02036","article-title":"Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline","volume":"40","author":"Mohile","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.phrs.2022.106316_bib11","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1200\/JCO.2004.06.082","article-title":"Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial","volume":"22","author":"Roa","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.phrs.2022.106316_bib12","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa065901","article-title":"Radiotherapy for glioblastoma in the elderly","volume":"356","author":"Keime-Guibert","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.phrs.2022.106316_bib13","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","article-title":"Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial","volume":"13","author":"Malmstr\u00f6m","year":"2012","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.phrs.2022.106316_bib14","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(12)70164-X","article-title":"Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial","volume":"13","author":"Wick","year":"2012","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.phrs.2022.106316_bib15","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2022.106316_bib16","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.ijrobp.2017.03.037","article-title":"Survival outcomes with short-course radiation therapy in elderly patients with glioblastoma: data from a randomized phase 3 trial","volume":"98","author":"Guedes de Castro","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"11","key":"10.1016\/j.phrs.2022.106316_bib17","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","article-title":"Short-course radiation plus temozolomide in elderly patients with glioblastoma","volume":"376","author":"Perry","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.phrs.2022.106316_bib18","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2022.106316_bib19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejca.2016.12.003","article-title":"Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma-A phase II multicentric, randomised study","volume":"73","author":"Ursu","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"10.1016\/j.phrs.2022.106316_bib20","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.phrs.2022.106316_bib21","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/annonc\/mdy120","article-title":"Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial","volume":"29","author":"Wirsching","year":"2018","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106316_bib22","first-page":"vdaa046","article-title":"Hydroxychloroquine and short-course radiotherapy in elderly patients with newly diagnosed high-grade glioma: a randomized phase II trial","volume":"2","author":"Brazil","year":"2020","journal-title":"Neurooncol. Adv."},{"issue":"5","key":"10.1016\/j.phrs.2022.106316_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156369","article-title":"Multi-center randomized phase II study comparing cediranib plus gefitinib with cediranib plus placebo in subjects with recurrent\/progressive glioblastoma","volume":"11","author":"Brown","year":"2016","journal-title":"PLoS One"},{"issue":"20","key":"10.1016\/j.phrs.2022.106316_bib24","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and Bevacizumab in progressive glioblastoma","volume":"377","author":"Wick","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2022.106316_bib25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1470-2045(18)30675-2","article-title":"Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"20","author":"Lombardi","year":"2019","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106316_bib26","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/neuonc\/noy200","article-title":"A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma","volume":"21","author":"Narita","year":"2019","journal-title":"Neuro-Oncology"},{"issue":"7","key":"10.1016\/j.phrs.2022.106316_bib27","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1158\/1078-0432.CCR-18-1140","article-title":"Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (ReACT): results of a double-blind randomized phase II trial","volume":"26","author":"Reardon","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2022.106316_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119368","article-title":"Small interfering RNA (siRNA) to target genes and molecular pathways in glioblastoma therapy: current status with an emphasis on delivery systems","volume":"275","author":"Mirzaei","year":"2021","journal-title":"Life Sci."},{"issue":"4","key":"10.1016\/j.phrs.2022.106316_bib29","first-page":"299","article-title":"Management of glioblastoma: state of the art and future directions","volume":"70","author":"Tan","year":"2020","journal-title":"CA Cancer J. Clin."},{"issue":"11","key":"10.1016\/j.phrs.2022.106316_bib30","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.phrs.2022.106316_bib31","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"7650","key":"10.1016\/j.phrs.2022.106316_bib32","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2022.106316_bib33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"7521","key":"10.1016\/j.phrs.2022.106316_bib34","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: combining direct and indirect evidence","volume":"331","author":"Caldwell","year":"2005","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.phrs.2022.106316_bib35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/0962280211432219","article-title":"A practical introduction to multivariate meta-analysis","volume":"22","author":"Mavridis","year":"2013","journal-title":"Stat. Methods Med. Res."},{"issue":"20","key":"10.1016\/j.phrs.2022.106316_bib36","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat. Med."},{"issue":"7414","key":"10.1016\/j.phrs.2022.106316_bib37","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.phrs.2022.106316_bib38","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J. Clin. Epidemiol."},{"issue":"7109","key":"10.1016\/j.phrs.2022.106316_bib39","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"23","key":"10.1016\/j.phrs.2022.106316_bib40","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1001\/jama.2015.16669","article-title":"Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial","volume":"314","author":"Stupp","year":"2015","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.phrs.2022.106316_bib41","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","article-title":"NovoTTF-100A versus physician\u2019s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality","volume":"48","author":"Stupp","year":"2012","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2022.106316_bib42","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41416-020-01136-5","article-title":"Tumour treating fields therapy for glioblastoma: current advances and future directions","volume":"124","author":"Rominiyi","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.phrs.2022.106316_bib43","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1158\/1078-0432.CCR-17-1117","article-title":"Tumor-treating fields: a fourth modality in cancer treatment","volume":"24","author":"Mun","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2022.106316_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103535","article-title":"Tumor-Treating Fields: A fourth modality in cancer treatment, new practice updates","volume":"168","author":"Arvind","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"10.1016\/j.phrs.2022.106316_bib45","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamaoncol.2017.5082","article-title":"Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial","volume":"4","author":"Taphoorn","year":"2018","journal-title":"JAMA Oncol."},{"issue":"18","key":"10.1016\/j.phrs.2022.106316_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202100978","article-title":"Electrotherapies for glioblastoma","volume":"8","author":"Jenkins","year":"2021","journal-title":"Adv. Sci."},{"issue":"4","key":"10.1016\/j.phrs.2022.106316_bib47","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0360-3016(94)90573-8","article-title":"A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme","volume":"29","author":"Bauman","year":"1994","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"7","key":"10.1016\/j.phrs.2022.106316_bib48","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.phrs.2022.106316_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103645","article-title":"Effectiveness of different treatment strategies in elderly patients with glioblastoma: an evidence map of randomised controlled trials","author":"Ma","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106316_bib50","article-title":"Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis","volume":"3","author":"Hanna","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"issue":"11","key":"10.1016\/j.phrs.2022.106316_bib51","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1158\/1078-0432.CCR-19-3359","article-title":"Determining the optimal adjuvant therapy for improving survival in elderly patients with glioblastoma: a systematic review and network meta-analysis","volume":"26","author":"Nassiri","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2022.106316_bib52","doi-asserted-by":"crossref","DOI":"10.1093\/noajnl\/vdac025","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase 3 trial","author":"Omuro","year":"2022","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.phrs.2022.106316_bib53","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase 3 trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","author":"Lim","year":"2022","journal-title":"Neuro-Oncology"},{"issue":"7","key":"10.1016\/j.phrs.2022.106316_bib54","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","article-title":"Current state of immunotherapy for glioblastoma","volume":"15","author":"Lim","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822002614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822002614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:36:14Z","timestamp":1760913374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661822002614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":54,"alternative-id":["S1043661822002614"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106316","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy and safety of therapeutics for elderly glioblastoma patients: A Bayesian network analysis","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106316","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106316"}}